Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,748,878
  • Shares Outstanding, K 53,710
  • Annual Sales, $ 0 K
  • Annual Income, $ -175,850 K
  • EBIT $ -89 M
  • EBITDA $ -87 M
  • 60-Month Beta -3.15
  • Price/Sales 25.18
  • Price/Cash Flow N/A
  • Price/Book 5.66

Options Overview Details

View History
  • Implied Volatility 76.67% (+6.82%)
  • Historical Volatility 106.22%
  • IV Percentile 69%
  • IV Rank 20.45%
  • IV High 218.78% on 03/26/25
  • IV Low 40.13% on 08/14/25
  • Expected Move (DTE 10) 5.59 (10.93%)
  • Put/Call Vol Ratio 2.73
  • Today's Volume 3,837
  • Volume Avg (30-Day) 3,080
  • Put/Call OI Ratio 0.67
  • Today's Open Interest 63,285
  • Open Int (30-Day) 92,251
  • Expected Range 45.59 to 56.77

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.52
  • Number of Estimates 6
  • High Estimate 0.70
  • Low Estimate 0.45
  • Prior Year -1.27
  • Growth Rate Est. (year over year) +140.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.20 +15.95%
on 11/21/25
53.10 -3.47%
on 12/04/25
+3.55 (+7.44%)
since 11/07/25
3-Month
41.80 +22.61%
on 11/07/25
72.88 -29.68%
on 10/16/25
-18.96 (-27.00%)
since 09/09/25
52-Week
41.50 +23.49%
on 01/15/25
90.32 -43.26%
on 07/09/25
+3.33 (+6.95%)
since 12/09/24

Most Recent Stories

More News
Johnson Fistel Begins Investigation on Behalf of Soleno Therapeutics, Inc. (SLNO) Shareholders Who Have Incurred Losses

SAN DIEGO , Dec. 4, 2025 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether Soleno Therapeutics, Inc. (NASDAQ: SLNO) or certain of its officers and directors...

SLNO : 51.25 (+0.14%)
Soleno Therapeutics Announces the Passing of Board Member William G. Harris

REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 51.25 (+0.14%)
Soleno Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

REDWOOD CITY, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 51.25 (+0.14%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Soleno Therapeutics, Inc. ("Soleno" or the "Company") (NASDAQ: SLNO). Such investors are...

SLNO : 51.25 (+0.14%)
SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ: SLNO)...

SLNO : 51.25 (+0.14%)
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement

REDWOOD CITY, Calif., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 51.25 (+0.14%)
INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation of Soleno Therapeutics, Inc. (NASDAQ: SLNO) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP  is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ("Soleno" or "the...

SLNO : 51.25 (+0.14%)
SLNO INVESTIGATION ALERT: Investigation Launched into Soleno Therapeutics, Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

SAN DIEGO , Nov. 7, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Soleno Therapeutics, Inc. (NASDAQ:...

SLNO : 51.25 (+0.14%)
Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman

SLNO Investors with Losses Encouraged to Contact Hagens Berman

SLNO : 51.25 (+0.14%)
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases,...

SLNO : 51.25 (+0.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

3rd Resistance Point 54.40
2nd Resistance Point 53.52
1st Resistance Point 52.35
Last Price 51.25
1st Support Level 50.30
2nd Support Level 49.42
3rd Support Level 48.25

See More

52-Week High 90.32
Fibonacci 61.8% 71.67
Fibonacci 50% 65.91
Fibonacci 38.2% 60.15
Last Price 51.25
52-Week Low 41.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar